Early Diagnosis Of Renal Cell Carcinoma Research Articles

The Application of Exosomes in the Diagnosis and Treatment of Renal Cell Carcinoma

Renal cell carcinoma (RCC) is an epithelial tumor originating from the proximal renal tubule of the urinary system. RCC is one of the most common and deadly tumors representing clear cell renal cell carcinoma (ccRCC) (about 75%) as major subtype characterized by high incidence and poor prognosis. There are no obvious clinical symptoms in the early stage ccRCC, but are readily visible in the late stage with >30% patients diagnosed with diffusion and metastasis. The incidence of RCC is higher in males than females and frequent in developed countries than in developing ones. The current treatment for rRCC mainly focuses on surgical excision and chemotherapy, however, it still suffers from high recurrence and poor survival, due to metastatic growth and insensitivity to radiotherapy and chemotherapy. Early diagnosis of RCC is very important and remains a top priority for its treatment. Exosomes are small vesicles with a lipid bilayer membrane structure that are actively secreted by normal and cancer cells in the body, containing bioactive substances such as proteins, nucleic acids, and lipids. The detection of extracellular vesicles in body fluids can play an important role in the early diagnosis of RCC. This article reviews the role of exosomes in the diagnosis and treatment of RCC.

Metabonome in Early Diagnosis of Renal Cell Carcinoma

Renal cell carcinoma(RCC)is one of the most common malignant tumors in the urinary system.Many patients have already been in the advanced stage at the first medical consultation and the prognosis is dismal.Metabonomics searches for differential metabolomes through high-throughput analysis of endogenous metabolites showing high potential in the early diagnosis of RCC and the investigations on its pathophysiological mechanisms.Metabonomics techniques are also useful for identifying tumor markers,which will help to enable early diagnosis and improve clinical prognosis of RCC.

Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma

Renal cell carcinoma (RCC) is the second-most common uronephrological cancer. In the absence of specific symptoms, early diagnosis of RCC is challenging. Monitoring of the aberrant expression of tumour-associated antigens (TAAs) and related autoantibody response is considered as a novel approach of RCC diagnostics. The aim of this study was to examine the aberrant expression of arrestin-1 in renal tumours, to investigate the possible epigenetic mechanism underlying arrestin-1 expression, and to assess the frequency of anti-arrestin-1 autoantibody response. Immunohistochemistry was used to assess the presence of arrestin-1 in primary tumours and metastases of 39 patients with RCC and renal oncocytoma. Bisulfite sequencing was employed to analyse the methylation status of the promoter of the SAG gene encoding arrestin-1. Western blot analysis was performed to detect autoantibodies against arrestin-1 in serum samples of 36 RCC and oncocytoma patients. Arrestin-1 was found to be expressed in RCC (58.7% of cases) and renal oncocytoma (90% of cases) cells, while being absent in healthy kidney. The expression of arrestin-1 in RCC metastases was more prominent than in primary tumours. Hypomethylation of the SAG gene promoter is unlikely to be the mechanism for the aberrant expression of arrestin-1. Autoantibodies against arrestin-1 were detected in sera of 75% of RCC patients. Taken together, our findings suggest employment of autoantibody against arrestin-1 as biomarker of RCC.

Lifestyle Risk Factors in the Development of Kidney Cancer: A Russian Experience

AbstractThe objective of our study was the evaluation of major lifestyle risk factors for the development of renal cell carcinoma (RCC) and the assessment of chances of developing this disease among inhabitants in the region, in the presence of and with combinations of the studied risk factors. Risk factors for developing RCC that are associated with lifestyle (smoking, obesity and hypertension) were observed in 500 patients with RCC aged 30-64 years who were investigated at the Krasnoyarsk Oncology Dispensary (study group) and 858 participants in the Krai (control group). The results of our study showed that smoking increases the risk of developing RCC 2.9 times and arterial hypertension 3.3 times in men; in women, obesity and hypertension increased these risks 2.6 and 3.2 times, respectively. All three risk factors were combined in 13.6% of men and in 8.4% of women with RCC. Our data may be useful for the prevention, development of screening programmes and early diagnosis of RCC.

In vitro selection of DNA aptamers against renal cell carcinoma using living cell-SELEX

Renal cell carcinoma (RCC) is the most common form of kidney cancer with poor prognosis. Early diagnosis of RCC would significantly improve patient prognosis and quality of life. In this work, we developed new aptamer probes for RCC by using cell-SELEX (systematic evolution of ligands by exponential enrichment) only after 12 rounds of selection, in which a clear cell renal cell carcinoma (ccRCC) cell line 786-O was used as target cell, and embryonic kidney cell line 293T as negative control cell. The selected aptamers were subjected to flow cytometry and laser confocal fluorescence microscopy to evaluate their binding affinity and selectivity. The dissociation constant Kd values of four selected aptamers are all in the nanomolar range. Aptamer W786-1 with the best binding affinity and a Kd value of 9.4 ± 2.0nM was further optimized and its truncated sequence W786-1S showed considerable affinity to 786-O cells. The proteinase and temperature treatment experiment indicated that W786-1 could recognize the target 786-O cells through surface proteins, and remain good binding affinity and excellent selectivity under physiological conditions. Therefore, on the basis of its excellent targeting properties and functional versatility, W786-1 holds great potential to be used as a molecular probe for identifying and targeting RCC.

IL1 genes polymorphism and the risk of renal cell carcinoma in Chinese Han population.

Renal cell carcinoma (RCC) is considered a cytokine-responsive tumor. However, with the lack of diagnostic screening biomarkers, early diagnosis of RCC is challenging. Our study was investigated the association of IL1 gene polymorphisms and RCC risk. We conducted a case-control study of 291 RCC cases and 463 controls to evaluation the IL1RN of single nucleotide polymorphisms (SNPs) on RCC risk. We selection of 16 SNPs in IL1RN, IL1A, IL1B genes were analyzed. Using the chi-squared (χ2) test and genetic model analysis, we found an association with RCC risk for five SNPs [rs3783550 (IL1A), rs3783546 (IL1A), rs1609682 (IL1A), rs3783521 (IL1A), and rs1143623 (IL1B)] and increased the risk of RCC. Stratified analyses show that smoking, not drinking and age>55 populations relative to nonsmoking, drinking and age<55 more susceptible. Our study suggested that IL1B and IL1A may involve in the development of RCC in Chinese Han population.

Multidetector computed tomography scan for renal cell carcinoma: A review

Renal cell carcinoma (RCC) is the most common renal malignant tumour. Owing to its retroperitoneal location, RCC remains asymptomatic and non-palpable until advanced disease develops. Most cases are identified during radiological examination for other reasons. The management of RCC depends substantially on the effective use of imaging. This is true in all the stages of the RCC, from initial diagnosis to follow-up. This article sets to review the current knowledge about multidetector computed tomography (MDCT) scan and how it characterises the RCC. A search of PubMed database was made to locate the original and review articles in English that address the MDCT scan or RCC, without limit to publication date. Relevant articles and textbook chapters were reviewed, analysed and summarised. MDCT reveals the renal tumour, its extent, venous involvement, status of loco-regional lymph nodes as well as adrenal and liver extension. It is available and relatively affordable presently in some centres across the subregion. MDCT is an essential tool that has aided not only the early diagnosis of RCC, but also the staging and characterisation of the RCC.